Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia

Journal of Clinical Oncology

Volumn 29, Issue 1, 2011, Pages 97-105

  Steensma, David P ^a   Sloan, Jeff A ^a   Dakhil, Shaker R ^a   Dalton, Robert ^a   Kahanic, Stephen P ^a   Prager, Diane J ^a   Stella, Philip J ^a   Rowland Jr , Kendrith M ^a   Novotny, Paul J ^a   Loprinzi, Charles L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC GLUCONATE; FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; TRANSFERRIN;

ADULT; ANEMIA; ARTICLE; CHEMOTHERAPY ASSOCIATED ANEMIA; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FEMALE; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANEMIA; ANTINEOPLASTIC AGENTS; DIETARY SUPPLEMENTS; ERYTHROPOIETIN; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; IRON; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 79951986687     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.3644     Document Type: Article

References (23)

1. Spivak JL: The anaemia of cancer: Death by a thousand cuts. Nat Rev Cancer 5:543-555, 2005
2. Bohlius J, Wilson J, Seidenfeld J, et al: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3:CD003407, 2006
3. Goodnough LT: Erythropoietin and iron-restricted erythropoiesis. Exp Hematol 35:167-172, 2007
4. Bohlius J: Is intravenous iron supplementation with erythropoiesis- stimulating agents beneficial in cancer patients with anemia? Nat Clin Pract Oncol 5:688-689, 2008
5. Auerbach M: Should intravenous iron be the standard of care in oncology? J Clin Oncol 26:1579-1581, 2008
6. Auerbach M, Ballard H, Trout JR, et al: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 22:1301-1307, 2004 (Pubitemid 41079845)
7. Henry DH, Dahl NV, Auerbach M, et al: Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12:231-242, 2007
8. Hedenus M, Birgegård G, Nasman P, et al: Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 21:627-632, 2007 (Pubitemid 46444544)
9. Pedrazzoli P, Farris A, Del Prete S, et al: Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26:1619-1625, 2008
10. Bastit L, Vandebroek A, Altintas S, et al: Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26:1611-1618, 2008
11. Rizzo JD, Somerfield MR, Hagerty KL, et al: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26:132-149, 2008
12. Aapro MS, Link H: September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13:33-36, 2008 (suppl 3)
13. McCorkle R, Young K: Development of a symptom distress scale. Cancer Nurs 1:373-378, 1978
14. Mendoza TR, Wang XS, Cleeland CS, et al: The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory. Cancer 85:1186-1196, 1999 (Pubitemid 29115600)
15. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13-19, 1997 (3 suppl 2)
16. Bretscher M, Rummans T, Sloan J, et al: Quality of life in hospice patients: A pilot study. Psychosomatics 40:309-313, 1999 (Pubitemid 29315951)
17. Sloan JA, Cella D, Frost M, et al: Assessing clinical significance in measuring oncology patient quality of life: Introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc 77:367-370, 2002 (Pubitemid 34260745)
18. Beguin Y, Maertens J, De Prijck B, et al: Darbepoetin-alfa and IV iron administration after autologous hematopoietic stem cell transplantation: A prospective randomized multicenter trial. ASH Annual Meeting Abstracts 112, 2008 (abstr 54)
19. Auerbach M, Silberstein PT, Webb RT, et al: Late-breaking abstract #9 of European Society Of Medical Oncology 2008 Annual Meeting: Darbepoetin alfa 500 mcg or 300 mcg once every three weeks with or without iron in patients with chemotherapy-induced anemia. Ann Oncol 19:viii3, 2008
20. Auerbach M, Ballard H: Intravenous iron in oncology. J Natl Compr Canc Netw 6:585-592, 2008; quiz 592 (Pubitemid 352007766)
21. Henry DH: The role of intravenous iron in cancer-related anemia. Oncology (Williston Park) 20:21-24, 2006 (suppl 6)
22. Finch CA: Anemia of chronic disease. Postgrad Med 64:107-113, 1978
23. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 352:1011-1023, 2005